{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-161087","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.556685+00:00","generated_at":"2026-06-01T04:20:59.980977+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Shattuck Labs reports 67% ORR in HR-MDS, 43% in TP53m AML from SL-172154 Phase 1B","bullets":["Observed 67% ORR in frontline HR-MDS patients (24 treated), with 42% complete remission rate; median survival not yet reached.","In 21 frontline TP53m AML patients, ORR 43% with 29% CR; median survival not reached; 5 patients bridged to transplant.","Manageable safety: no grade 3+ IRRs with dexamethasone premedication; no hemolytic anemia; deaths unrelated to SL-172154.","Company focusing later-stage development on HR-MDS and TP53m AML; no further PROC development due to competitive landscape.","Enrollment underway for randomized controlled HR-MDS cohort; regulatory discussions expected later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-161087","json":"https://secwatch.observer/filing/0001193125-24-161087.json","markdown":"https://secwatch.observer/filing/0001193125-24-161087.md","text":"https://secwatch.observer/filing/0001193125-24-161087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524161087/0001193125-24-161087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000119312524161087/d841424d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:20:59.980977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}